Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):630-639. doi: 10.1016/j.ijrobp.2018.02.032. Epub 2018 Mar 6.
To determine whether local excision (LE) outcomes were comparable to total mesorectal excision (TME) outcomes in node-positive (cN+) rectal cancer patients who were good responders.
This retrospective study included clinical T2-3 and cN+ low rectal cancer patient who received preoperative chemoradiotherapy (PCRT) followed by TME or LE. Clinical stage T1 or T4 tumors, upper-to-middle rectal tumors (>7 cm from anal verge), and synchronous distant metastases were excluded. Lymph nodes ≥5 mm in size were defined as tumor-positive, and patients with metastatic lymph nodes >20 mm in size were excluded. Preoperative chemoradiotherapy comprised radiation (50-50.4 Gy/25-28 fractions over 5 weeks) with 2 cycles of 5-fluorouracil or oral capecitabine. Propensity scores were computed from tumor and patient variables and used for 1-to-1 matched analysis. Local recurrence-free survival, disease-free survival, and overall survival were compared between the 2 matched groups.
Between January 2007 and December 2013, 563 and 55 patients underwent TME and LE, respectively. The median follow-up period was 54 months. In propensity score-matched analysis, 48 patients were included in each group. No statistical differences were observed in 3-year local recurrence-free survival (97.9% vs 97.9%, P = .994), 3-year disease-free survival (91.5% vs 91.4%, P = .968), or 3-year OS (93.7% vs 97.9%, P = .809) between the TME and LE groups.
In clinical N+ rectal cancer patients, oncologic outcomes of PCRT followed by LE were comparable to those of TME; this finding might be applicable only to those patients with good response in the primary tumor and small lymph node metastases.
确定对于经新辅助放化疗(PCRT)后行局部切除术(LE)或全直肠系膜切除术(TME)的肿瘤反应良好的淋巴结阳性(cN+)直肠腺癌患者,LE 的局部复发结局是否与 TME 相当。
本回顾性研究纳入了临床 T2-3 期和 cN+低位直肠癌患者,他们在接受 PCRT 后行 TME 或 LE。排除临床 T1 或 T4 期肿瘤、中上段直肠肿瘤(距肛缘>7cm)和同步远处转移。淋巴结直径≥5mm 定义为肿瘤阳性,排除淋巴结转移灶>20mm 的患者。术前放化疗包括放疗(50-50.4Gy/25-28 次分割,共 5 周),联合氟尿嘧啶或卡培他滨 2 个周期。使用肿瘤和患者变量计算倾向评分,并进行 1:1 匹配分析。比较两组患者的局部无复发生存率、无病生存率和总生存率。
2007 年 1 月至 2013 年 12 月,分别有 563 例和 55 例患者行 TME 和 LE。中位随访时间为 54 个月。在倾向评分匹配分析中,每组纳入 48 例患者。TME 组和 LE 组的 3 年局部无复发生存率(97.9% vs 97.9%,P=0.994)、3 年无病生存率(91.5% vs 91.4%,P=0.968)和 3 年总生存率(93.7% vs 97.9%,P=0.809)差异均无统计学意义。
对于临床 cN+直肠腺癌患者,PCRT 后行 LE 的肿瘤学结局与 TME 相当;这一发现可能仅适用于原发肿瘤反应良好且淋巴结转移较小的患者。